Gene-based medicines

Transforming the lives of patients                            with serious diseases

Corporate Presentation

OVERVIEW

Stock Information


Nov 21, 2018 10:48 AM EST
Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

Nov 21, 2018

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 09, 2018

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

Nov 07, 2018

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

Oct 10, 2018

CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

View All

Upcoming Events & Recent Presentations

Nov 29, 2018 at 4:00 PM EST
Barclays Gene Editing & Gene Therapy Summit
Nov 28, 2018 at 10:30 AM EST
The 30th Annual Piper Jaffray Healthcare Conference
Nov 2018
2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function
Nov 2018
CRISPR Therapeutics Corporate Presentation
May 2018
2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
Apr 2018
2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells
Apr 2018
2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen

View All